Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era

Alfonso Piciocchi, Sabina Chiaretti, Marta Cipriani, Monica Messina, Loredana Elia, Irene Della Starza, Antonella Vitale, Paola Fazi, Marco Vignetti, Robin Foa

Blood (2023) 142 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2023-179102

Published: 2023

Journal Articles

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Maria Cristina Puzzolo, Giulia Radice, Nadia Peragine, Maria Stefania de Propris, Paola Mariglia, Marco Vignetti, Antonella Vitale, Renato Bassan, Mario Annunziata, Gianluca Gaidano, Alessandro Rambaldi, Sabina Chiaretti, Anna Guarini, Robin Foà

Blood (2021) 138 (22): 2290–2293.

https://doi.org/10.1182/blood.2021011822

Published: 2021

Includes: Supplemental data

Journal Articles

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Blood (2021) 138 (Supplement 1): 3408.

https://doi.org/10.1182/blood-2021-147325

Published: 2021

Journal Articles

Prognostic Impact of t(4;11)(q21;q23)/ KMT2A-AFF1 -Positivity in 926 BCR-ABL1 -Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996

Alfonso Piciocchi, Monica Messina, Loredana Elia, Bs, Antonella Vitale, MD, Stefano Soddu, Anna Maria Testi, MD, Sabina Chiaretti, MD PhD, Marco Mancini, MD, Giorgina Specchia, MD, Antonio Spadano, MD, Mauro Krampera, Roberto Cairoli, MD, Francesco Di Raimondo, MD, Felicetto Ferrara, MD, Giuseppe Cimino, MD, Renato Bassan, MD, Paola Fazi, MD, Marco Vignetti, MD

Blood (2019) 134 (Supplement_1): 1469.

https://doi.org/10.1182/blood-2019-121977

Published: 2019

Journal Articles

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Michela Ansuinelli, MD, Antonella Vitale, MD, Giovanna Pecoraro, MD, Saveria Capria, MD, Silvia Maria Trisolini, MD, Clara Minotti, MD, Claudio Cartoni, MD, Anna Maria Testi, MD, Maria Luisa Moleti, MD, Anna Paola Iori, MD, Walter Barberi, MD PhD, Irene Della Starza, PhD, Loredana Elia, Bs, Francesca Mancini, Maria Stefania De Propris, Anna Guarini, PhD, Sabina Chiaretti, MD PhD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 5121.

https://doi.org/10.1182/blood-2019-128156

Published: 2019

Journal Articles

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Sabina Chiaretti, MD PhD, Renato Bassan, MD, Antonella Vitale, MD, Loredana Elia, Bs, Alfonso Piciocchi, Cristina Puzzolo, PhD, Martina Canichella, MD, Felicetto Ferrara, MD, Monia Lunghi, MD PhD, Francesco Fabbiano, MD, Massimiliano Bonifacio, MD, Nicola Fracchiolla, Prassede Salutari, MD, Alessandra Mancino, Bs, Marco Vignetti, MD, Anna Guarini, PhD, Alessandro Rambaldi, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 740.

https://doi.org/10.1182/blood-2019-128759

Published: 2019

Journal Articles

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

Irene Della Starza, PhD, Lucia Anna De Novi, PhD, Alessandra Santoro, PhD, Salemi Domenico, PhD, Marzia Cavalli, PhD, Roberta Soscia, Francesca Paoloni, Lucia Menale, Valerio Apicella, Caterina Ilari, PhD, Antonella Vitale, Marco Vignetti, MD, Renato Bassan, MD, Sabina Chiaretti, MD PhD, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2018-99-118219

Published: 2018

Journal Articles

First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 99.

https://doi.org/10.1182/blood.V130.Suppl_1.99.99

Published: 2017

Journal Articles

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2016) 128 (22): 176.

https://doi.org/10.1182/blood.V128.22.176.176

Published: 2016

Journal Articles

Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification

Blood (2015) 126 (23): 81.

https://doi.org/10.1182/blood.V126.23.81.81

Published: 2015

Journal Articles

Rapid Identification of BCR/ABL1 -like Acute Lymphoblastic Leukemia (ALL) Cases By Quantitative Real Time-PCR (Q-RT-PCR). Generation and Validation of a Predictive Statistical Model

Sabina Chiaretti, Sara Grammatico, Alfonso Piciocchi, Monica Messina, Anna Lucia Fedullo, Valentina Gianfelici, Grazia Fazio, PhD, Nadia Peragine, Maria Paola Martelli, Paola Fazi, Marco Vignetti, Antonella Vitale, Cyril Salek, Gianni Cazzaniga, PhD, Anna Guarini, Robin Foà

Blood (2015) 126 (23): 1410.

https://doi.org/10.1182/blood.V126.23.1410.1410

Published: 2015

Journal Articles

First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients

Blood (2014) 124 (21): 797.

https://doi.org/10.1182/blood.V124.21.797.797

Published: 2014

Journal Articles

Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients

Giovanni Fernando Torelli, MD, Nadia Peragine, PhD, Sara Raponi, PhD, Paola Mariglia, BS, Simona Pauselli, MD, Maria Stefania De Propris, PhD, Antonella Vitale, Anna Guarini, Robin Foá, MD

Blood (2013) 122 (21): 2026.

https://doi.org/10.1182/blood.V122.21.2026.2026

Published: 2013

Journal Articles

Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis

Blood (2013) 122 (21): 2622.

https://doi.org/10.1182/blood.V122.21.2622.2622

Published: 2013

Journal Articles

Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies

Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Cristina Papayannidis, Paola Bresciani, Valeria Coluccio, Ilaria Iacobucci, Claudia Venturi, Mario Luppi, Emanuela Ottaviani, Federica Cattina, Robin Foà, MD, Antonella Vitale, Domenico Russo, Michele Baccarani, MD, Giovanni Martinelli

Blood (2012) 120 (21): 284.

https://doi.org/10.1182/blood.V120.21.284.284

Published: 2012

Journal Articles

Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.

Blood (2012) 120 (21): 2601.

https://doi.org/10.1182/blood.V120.21.2601.2601

Published: 2012

Journal Articles

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Blood (2011) 118 (25): 6521–6528.

https://doi.org/10.1182/blood-2011-05-351403

Published: 2011

Journal Articles

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Blood (2011) 118 (21): 575.

https://doi.org/10.1182/blood.V118.21.575.575

Published: 2011

Journal Articles

Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,

Simona Soverini, Caterina De Benedittis, Alessandra Gnani, Ilaria Iacobucci, PhD, Domenico Russo, Federica Cattina, MD, Fausto Castagnetti, Gabriele Gugliotta, Cristina Papayannidis, Antonella Vitale, Loredana Elia, Robin Foà, Francesca Palandri, Annalisa Lonetti, Maria Teresa Bochicchio, Sandra Durante, Gianantonio Rosti, MD, Michele Baccarani, MD, Giovanni Martinelli

Blood (2011) 118 (21): 3775.

https://doi.org/10.1182/blood.V118.21.3775.3775

Published: 2011

NARROW

A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era

Host immune system modulation in Ph + acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab

Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study

Prognostic Impact of t(4;11)(q21;q23)/ KMT2A-AFF1 -Positivity in 926 BCR-ABL1 -Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996

Role of Blinatumomab in Minimal Residual Disease and Hematologic Relapsed/Refractory Adult Acute Lymphoblastic Leukemia Patients Treated over 5 Years. a Single Center Experience

Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial

Comparative Analysis between RQ-PCR, Digital-Droplet-PCR and Next-Generation-Sequencing (NGS) of Immunoglobulin/T-Cell Receptor Gene Rearrangements to Monitor Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia Patients

First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Final Results of Northern Italy Leukemia Group (NILG) Trial 10/07 Combining Pediatric-Type Therapy with Minimal Residual Disease Study and Risk-Oriented Hematopoietic Cell Transplantation in Adult Acute Lymphoblastic Leukemia (ALL)

Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification

Rapid Identification of BCR/ABL1 -like Acute Lymphoblastic Leukemia (ALL) Cases By Quantitative Real Time-PCR (Q-RT-PCR). Generation and Validation of a Predictive Statistical Model

First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients

Expanded Natural Killer Cells For The Control Of Minimal Residual Disease In Ph+ Acute Lymphoblastic Leukemia Patients

Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis

Whole Transcriptome Sequencing In Refractory T-Cell Acute Lymphoblastic Leukemia

Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies

Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2 nd -Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement

Ultra-Deep Amplicon Sequencing Using Roche 454 Technology Allows High Sensitivity Bcr-Abl Kinase Domain Mutation Screening and Anticipates Emerging Mutations Leading to Resistance to Tyrosine Kinase Inhibitors in Philadelphia-Positive Leukemia Patients,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only